RUDOLPH DOROTHEA - boehringer ingelheim int co

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 45 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Discovery and Characterization of Brigimadlin, a Novel and Highly Potent MDM2–p53 Antagonist Suitable for Intermittent Dose Schedules

Andreas Gollner,Dorothea Rudolph,Ulrike Weyer-Czernilofsky,Rosa Baumgartinger, Peter Jung,Harald Weinstabl,Jürgen Ramharter,Rolf Grempler,Jens Quant,Jörg Rinnenthal,Alejandro Pérez Pitarch, Bojana Golubovic,Daniel Gerlach,Gerd Bader, Kristiane Wetzel, Sebastian Otto, Christian Mandl,Guido Boehmelt,Darryl B McConnell,Norbert Kraut,Patrizia Sini

Molecular cancer therapeutics (2024)

Cited0Views0WOSBibtex

Discovery of a Myeloid Cell Leukemia 1 (Mcl-1) Inhibitor That Demonstrates Potent in Vivo Activities in Mouse Models of Hematological and Solid Tumors

JOURNAL OF MEDICINAL CHEMISTRYno. 16 (2024): 14370-14393

Cited0Views0WOSBibtex

KRASmulti Inhibitor BI 3706674, an Orally Bioavailable, Direct Inhibitor of Diverse Oncogenic KRAS Variants Drives Tumor Regression in KRASG12V-driven Preclinical Models

David Hwa Peng, Antonio Tedeschi, Lorenz Herdeis,Otmar Schaaf,Fabio Savarese, Francesca Rocchetti,Johannes Popow, Heinrich J. Huber,Birgit Wilding,Matthias Treu,Julian Fuchs,Joachim Broeker,Tobias Wunberg, Firoella Schischlik,Jesse Lipp, Mariah Williams, Vaness Chandler, Charles E. Deckard,Vandhana Ramamoorthy, Joseph R. Daniele,Scott Kopetz, Michael Kim,Don L. Gibbons, Christopher P. Vellano, Joseph R. Marszalek,TImothy P. Heffernan,Darryl McConnell,Mark Pearson, Norbert Kraut,Dorothea Rudolph

CANCER RESEARCHno. 6 (2024)

Cited0Views0Bibtex

Abstract 3317: KRASmulti Inhibitor BI 3706674 Shows Efficacy in KRAS-driven Preclinical Models of Cancer That Supports Clinical Testing in Patients with Tumors Harbouring KRASG12V Mutations and KRAS Wild-Type Amplifications

Antonio Tedeschi,David H. Peng,Fiorella Schischlik,Lorenz Herdeis,Otmar Schaaf,Valeria Santoro,Daniel Gerlach,Fabio Savarese,Jesse J. Lipp, Christian Haslinger,Francesca Rocchetti,Johannes Popow,Heinrich J. Huber,Birgit Wilding, Matthias Treu,Julian E. Fuchs,Joachim Bröeker, Tobias Wunber,Michael Gmachl,Klaus Rumpel,Matthew G. Rees, M. Ron,Jennifer A. Roth, Mariah Williams,Charles Deckard,Vandhana Ramamoorthy,Joseph R. Daniele,Jaffer A. Ajani, Funda Meric‐Bernstam,Scott Kopetz,Michael P. Kim,Don L. Gibbons,Christopher P. Vellano,Joseph R. Marszalek,Timothy P. Heffernan,Darryl B. McConnell, Mark Pearson, Norbert Kraut,Dorothea Rudolph

Cancer researchno. 6_Supplement (2024): 3317-3317

Cited0Views0Bibtex

Abstract 3321: KRASmulti Inhibitor BI 3706674, an Orally Bioavailable, Direct Inhibitor of Diverse Oncogenic KRAS Variants Drives Tumor Regression in KRASG12V-driven Preclinical Models

Cancer Researchno. 6_Supplement (2024): 3321-3321

Cited0Views0Bibtex

Supplementary Figure S1: Chemical Structure of the AK-B Inhibitor BI 811283. from Pharmacological Profile of BI 847325, an Orally Bioavailable, ATP-Competitive Inhibitor of MEK and Aurora Kinases

Patrizia Sini,Ulrich Gürtler,Stephan K. Zahn, C. Baumann,Dorothea Rudolph,Rosa Baumgartinger,Eva Strauss,Christian Haslinger,Ulrike Tontsch-Grunt,Irene C. Waizenegger, Flavio Solca,Gerd Bader, Andreas Zoephel,Matthias Treu,Ulrich Reiser,Pilar Garin‐Chesa,Guido Boehmelt, Norbert Kraut,Jens Quant,Günther R. Adolf

openalex

Cited0Views0Bibtex

BI KRASmulti, a First-in-class, Orally Bioavailable and Direct Inhibitor of Diverse Oncogenic KRAS Variants Drives Tumor Regression in Preclinical Models and Validates Wild-Type Amplified KRAS As a Therapeutic Target

Antonio Tedeschi,Lorenz Herdeis,Valeria Santoro,Fabio Savarese,Birgit Wilding,Matthias Treu,Julian Fuchs,Joachim Broker,Tobias Wunberg,Michael Gmachl,Rumpel Klaus,Fiorella Schischlik,Jesse Lipp,David H. Peng, Mariah Williams,Charles Deckard,Vandhana Ramamoorthy,Joseph R. Daniele,Jaffer A. Ajani,Funda Meric-Bernstam, Christopher R. Vellano,Joseph R. Marszalek,Timothy P. Heffernan,Darryl McConnell,Mark Pearson, Norbert Kraut,Dorothea Rudolph

MOLECULAR CANCER THERAPEUTICSno. 12 (2023)

Cited0Views0Bibtex

Pan-KRAS Inhibitor Disables Oncogenic Signalling and Tumour Growth

Natureno. 7968 (2023): 160-166

Cited0Views0WOSNATUREBibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn